January 19, 2021
The Pharma Letter
WuXi Biologics and Oxford BioTherapeutics join forces on second bispecific program
Shanghai's WuXi Biologics and Oxford BioTherapeutics have advanced their immuno-oncology partnership.... See more »
Press Release: Oxford BioTherapeutics : Invenra and Oxford BioTherapeutics Enter Collaboration to Discover Novel Therapeutic Antibodies Targeting Cancer
MADISON, Wis. and OXFORD, England, June 25, 2015 /PRNewswire/ -- Invenra, Inc., a pre-clinical stage bio-pharmaceutical company focused on next-generation therapeutic human antibodies and antibody derivatives, and Oxford BioTherapeutics (OBT), an international, clinical stage...
Read full article »January 19, 2021
The Pharma Letter
WuXi Biologics and Oxford BioTherapeutics join forces on second bispecific program
Shanghai's WuXi Biologics and Oxford BioTherapeutics have advanced their immuno-oncology partnership.... See more »
Est. Annual Revenue
Est. Employees
Founder & CEO
Christian Rohlff
OBT is a biotechnology company that focuses on the discovery and development of therapeutics for the treatment of cancer. Read more
